Revolutionizing Obesity Treatment | Metsera
We are a clinical-stage biotechnology company focused on engineering, developing, manufacturing, and ultimately commercializing a new generation of potent, ultra-long acting, …
Metsera, Maze secure combined $415 million in IPOs
1 day ago · Metsera, an obesity drug developer, sold nearly 15.3 million shares at $18 apiece in an offering that ranks as one of the industry’s largest since 2022, according to BioPharma Dive …
Weight-loss drug developer Metsera targets up to $1.78 billion ...
3 days ago · Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable …
GLP-1RA developer Metsera targets $289m IPO
2 days ago · US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape …
Metsera Touts ‘Powerful’ Weight Loss Results—Again
Jan 7, 2025 · Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11% average body weight reduction at 12 …
Metsera reveals data supporting long-acting obesity shot
Jan 7, 2025 · Privately-held biotechnology startup Metsera said Tuesday a long-acting GLP-1 shot it’s developing helped people who are overweight or have obesity lose more weight than …
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Sep 24, 2024 · Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the …
Metsera Launches to Lead the Next Generation of Medicines for …
NEW YORK, April 18, 2024 -- (BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and …
Metsera News | Latest Updates on Innovations and Achievements
Stay updated with Metsera's latest news, achievements, and advancements in obesity and metabolic disease treatments. Discover our journey and innovations.
Arch-backed obesity biotech launches with $290M - Fierce Biotech
Apr 18, 2024 · Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. “It's …
- Some results have been removed